Published in J Vasc Interv Radiol on September 01, 2004
Endovascular intervention for peripheral artery disease. Circ Res (2015) 0.96
Percutaneous endovascular management of atherosclerotic axillary artery stenosis: Report of 2 cases and review of literature. World J Cardiol (2011) 0.80
Comparison of diamond-like carbon-coated nitinol stents with or without polyethylene glycol grafting and uncoated nitinol stents in a canine iliac artery model. Br J Radiol (2011) 0.76
Endovascular revascularization for aortoiliac atherosclerotic disease. Vasc Health Risk Manag (2016) 0.75
Comparison of Open-Cell Stent and Closed-Cell Stent for Treatment of Central Vein Stenosis or Occlusion in Hemodialysis Patients. Iran J Radiol (2016) 0.75
Effects of antiplatelet agents and other factors on neointimal proliferation in iliac artery stenting: intravascular ultrasound analysis. Ann Vasc Dis (2009) 0.75
Comparing the SMART stent with the Wallstent iliac endoprosthesis: reading between the lines. J Vasc Interv Radiol (2004) 0.75
Iliac arteries: how registries can help improve outcomes. Semin Intervent Radiol (2014) 0.75
Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med (2010) 17.57
Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med (2003) 13.29
Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med (2004) 12.58
A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med (2004) 11.86
Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med (2013) 8.91
Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med (2014) 5.88
Comparative effectiveness of revascularization strategies. N Engl J Med (2012) 5.49
Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation (2011) 5.16
Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease. N Engl J Med (2015) 3.69
Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium. J Am Coll Cardiol (2011) 3.37
TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J Biol Chem (2009) 3.29
One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation (2004) 3.23
Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. N Engl J Med (2015) 2.97
Evaluation of the safety and effectiveness of renal artery stenting after unsuccessful balloon angioplasty: the ASPIRE-2 study. J Am Coll Cardiol (2005) 2.87
Zotarolimus-eluting peripheral stents for the treatment of erectile dysfunction in subjects with suboptimal response to phosphodiesterase-5 inhibitors. J Am Coll Cardiol (2012) 2.85
Factors affecting long-term survival following renal artery stenting. Catheter Cardiovasc Interv (2007) 2.83
The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol (2004) 2.78
2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2011) 2.71
Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv (2011) 2.57
Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials. J Am Coll Cardiol (2008) 2.54
Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation (2002) 2.53
Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv (2010) 2.52
Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation (2004) 2.35
Clinical features and outcomes of carotid artery stenting by clinical expert consensus criteria: a report from the CARE registry. Catheter Cardiovasc Interv (2010) 2.21
Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials. JACC Cardiovasc Interv (2009) 2.12
Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium. Eur Heart J (2011) 2.11
Use of a constitutively active hypoxia-inducible factor-1alpha transgene as a therapeutic strategy in no-option critical limb ischemia patients: phase I dose-escalation experience. Circulation (2007) 2.07
Effect of endothelial shear stress on the progression of coronary artery disease, vascular remodeling, and in-stent restenosis in humans: in vivo 6-month follow-up study. Circulation (2003) 2.04
Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. JAMA (2006) 2.03
Screening for abdominal aortic aneurysm: a consensus statement. J Vasc Surg (2004) 1.96
Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial. J Endovasc Ther (2012) 1.95
No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Am Heart J (2003) 1.87
Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation (2004) 1.83
A randomized comparison of the Endeavor zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial. J Am Coll Cardiol (2010) 1.80
The United States preventive services task force recommendation statement on screening for peripheral arterial disease: more harm than benefit? Circulation (2006) 1.76
The Carotid Artery Revascularization and Endarterectomy (CARE) registry: objectives, design, and implications. Catheter Cardiovasc Interv (2008) 1.75
The United States Registry for Fibromuscular Dysplasia: results in the first 447 patients. Circulation (2012) 1.75
Recommendations for successful training on methods of delivery of biologics for cardiac regeneration: a report of the International Society for Cardiovascular Translational Research. JACC Cardiovasc Interv (2010) 1.74
Performance goals and endpoint assessments for clinical trials of femoropopliteal bare nitinol stents in patients with symptomatic peripheral arterial disease. Catheter Cardiovasc Interv (2007) 1.72
Carotid artery stenting is associated with increased complications in octogenarians: 30-day stroke and death rates in the CREST lead-in phase. J Vasc Surg (2004) 1.71
Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial. JACC Cardiovasc Interv (2009) 1.70
Three-year results of the VIBRANT trial of VIABAHN endoprosthesis versus bare nitinol stent implantation for complex superficial femoral artery occlusive disease. J Vasc Surg (2013) 1.68
Vascular health in Kawasaki disease. J Am Coll Cardiol (2013) 1.67
Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol (2002) 1.62
Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther (2006) 1.61
Incidence and predictors of late total occlusion following coronary stenting. Catheter Cardiovasc Interv (2003) 1.61
Saphenous vein graft stenting and major adverse cardiac events: a predictive model derived from a pooled analysis of 3958 patients. Circulation (2008) 1.59
May-Thurner syndrome in patients with cryptogenic stroke and patent foramen ovale: an important clinical association. Stroke (2009) 1.58
A decade of improvement in the clinical outcomes of percutaneous coronary intervention for multivessel coronary artery disease. Circulation (2002) 1.58
Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol (2006) 1.56
Excimer laser with adjunctive balloon angioplasty and heparin-coated self-expanding stent grafts for the treatment of femoropopliteal artery in-stent restenosis: twelve-month results from the SALVAGE study. Catheter Cardiovasc Interv (2012) 1.56
The truth and consequences of the COURAGE trial. J Am Coll Cardiol (2007) 1.55
Five-year clinical follow-up after intracoronary radiation: results of a randomized clinical trial. Circulation (2002) 1.55
Treatment of left anterior descending coronary artery disease with sirolimus-eluting stents. Circulation (2004) 1.54
Sirolimus-eluting stent for treatment of complex in-stent restenosis: the first clinical experience. J Am Coll Cardiol (2003) 1.53
Blood pressure response to renal artery stenting in 901 patients from five prospective multicenter FDA-approved trials. Catheter Cardiovasc Interv (2013) 1.52
In-stent restenosis and remote coronary lesion progression are coupled in cardiac transplant vasculopathy but not in native coronary artery disease. J Am Coll Cardiol (2006) 1.52
Differential mortality risk of postprocedural creatine kinase-MB elevation following successful versus unsuccessful stent procedures. J Am Coll Cardiol (2004) 1.52
Cryoplasty for the treatment of femoropopliteal arterial disease: results of a prospective, multicenter registry. J Vasc Interv Radiol (2005) 1.51
Induction of mild systemic hypothermia with endovascular cooling during primary percutaneous coronary intervention for acute myocardial infarction. J Am Coll Cardiol (2002) 1.51
Optimizing rotational atherectomy in high-risk percutaneous coronary interventions: insights from the PROTECT ΙΙ study. Catheter Cardiovasc Interv (2013) 1.50
TAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions. Eur Heart J (2007) 1.50
Prediction of long-term mortality after percutaneous coronary intervention in older adults: results from the National Cardiovascular Data Registry. Circulation (2012) 1.50
A randomized, controlled, multicenter trial to evaluate the safety and efficacy of zotarolimus- versus paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries The ZoMaxx I trial. JACC Cardiovasc Interv (2008) 1.47
Recombinant urokinase is safe and effective in restoring patency to occluded central venous access devices: a multiple-center, international trial. Crit Care Med (2004) 1.47
Excimer laser recanalization of femoropopliteal lesions and 1-year patency: results of the CELLO registry. J Endovasc Ther (2009) 1.47
The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation (2006) 1.46
Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up. Circulation (2002) 1.46
Objective performance goals of safety and blood pressure efficacy for clinical trials of renal artery bare metal stents in hypertensive patients with atherosclerotic renal artery stenosis. Catheter Cardiovasc Interv (2011) 1.44
An integrated TAXUS IV, V, and VI intravascular ultrasound analysis of the predictors of edge restenosis after bare metal or paclitaxel-eluting stents. Am J Cardiol (2008) 1.44
High-frequency vibration for the recanalization of guidewire refractory chronic total coronary occlusions. Catheter Cardiovasc Interv (2008) 1.42
Platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment during saphenous vein graft stenting: differential effects after randomization to occlusion or filter-based embolic protection. Eur Heart J (2006) 1.42
Two-year clinical outcomes after paclitaxel-eluting stent or brachytherapy treatment for bare metal stent restenosis: the TAXUS V ISR trial. Eur Heart J (2008) 1.41
Proper patient selection yields significant and sustained reduction in systolic blood pressure following renal artery stenting in patients with uncontrolled hypertension: long-term results from the HERCULES trial. J Clin Hypertens (Greenwich) (2014) 1.40
Risk adjustment for case mix and the effect of surgeon volume on morbidity. JAMA Surg (2013) 1.40
Angiographic outcome after intracoronary X-Sizer helical atherectomy and thrombectomy: first use in humans. Catheter Cardiovasc Interv (2002) 1.39
In-hospital and nine-month outcomes among patients with coronary lesions involving a side branch and treated with bare metal stents. Catheter Cardiovasc Interv (2010) 1.39
The SIRIUS-DIRECT trial: a multi-center study of direct stenting using the sirolimus-eluting stent in patients with de novo native coronary artery lesions. Catheter Cardiovasc Interv (2007) 1.38
Recertification in interventional cardiology. JACC Cardiovasc Interv (2008) 1.37
Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA Guideline Recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 1.36
Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials. Diabetes Care (2005) 1.35
Motor mechanism for protein threading through Hsp104. Mol Cell (2009) 1.33
Protected carotid stenting in high-risk patients with severe carotid artery stenosis. J Am Coll Cardiol (2006) 1.31
Prediction of sites of coronary atherosclerosis progression: In vivo profiling of endothelial shear stress, lumen, and outer vessel wall characteristics to predict vascular behavior. Curr Opin Cardiol (2003) 1.29
Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts. Circulation (2003) 1.27
Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial. J Am Coll Cardiol (2009) 1.26
Report of the National Heart, Lung, and Blood Institute working group on the translation of cardiovascular molecular imaging. Circulation (2011) 1.23
Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. J Vasc Surg (2002) 1.21